Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
DUETACT vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
Initial: 15 mg pioglitazone/500 mg metformin twice daily or 30 mg pioglitazone/500 mg metformin once daily. Titrate gradually based on glycemic response. Maximum: 45 mg pioglitazone/2000 mg metformin per day in divided doses.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Metformin: 6.2 hours (increased in renal impairment). Pioglitazone: 3-7 hours (parent), 16-24 hours (active metabolites), requiring once-daily dosing.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Metformin: 90% renal (unchanged), 10% fecal. Pioglitazone: 60-70% renal (metabolites), 20-30% fecal.
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione